Induction of a specific antibody response to Bordetella pertussis antigens in cultures of human peripheral blood mononuclear cells

Giacomini, Elena; Urbani, Francesca; Ausiello, Clara Maria; Luzzati, Alma L.

doi:10.1099/00222615-48-12-1081

Cited by 6 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No clear correlate-of-protection (CoP) against pertussis disease has been identified which could inform vaccine development and licensure [ 57 , 58 ]. Pertussis-specific serum antibody response is important in limiting severity of disease [ 59 ] and to some extent infection, however, the currently available antibody assays are insufficient to represent a CoP [ 60 , 61 , 62 ]. Cell-mediated immunity (CMI) is increasingly thought to play a key role in both vaccine efficacy and longevity of protection, via effector mechanisms as well as influence on magnitude, quality and longevity of the broader immune response [ 41 , 63 , 64 ].…”

Section: Introductionmentioning

confidence: 99%

Vaccine-Induced Cellular Immunity against Bordetella pertussis: Harnessing Lessons from Animal and Human Studies to Improve Design and Testing of Novel Pertussis Vaccines

2021

View full text Add to dashboard Cite

Pertussis (‘whooping cough’) is a severe respiratory tract infection that primarily affects young children and unimmunised infants. Despite widespread vaccine coverage, it remains one of the least well-controlled vaccine-preventable diseases, with a recent resurgence even in highly vaccinated populations. Although the exact underlying reasons are still not clear, emerging evidence suggests that a key factor is the replacement of the whole-cell (wP) by the acellular pertussis (aP) vaccine, which is less reactogenic but may induce suboptimal and waning immunity. Differences between vaccines are hypothesised to be cell-mediated, with polarisation of Th1/Th2/Th17 responses determined by the composition of the pertussis vaccine given in infancy. Moreover, aP vaccines elicit strong antibody responses but fail to protect against nasal colonisation and/or transmission, in animal models, thereby potentially leading to inadequate herd immunity. Our review summarises current knowledge on vaccine-induced cellular immune responses, based on mucosal and systemic data collected within experimental animal and human vaccine studies. In addition, we describe key factors that may influence cell-mediated immunity and how antigen-specific responses are measured quantitatively and qualitatively, at both cellular and molecular levels. Finally, we discuss how we can harness this emerging knowledge and novel tools to inform the design and testing of the next generation of improved infant pertussis vaccines.

show abstract

Section: Introductionmentioning

confidence: 99%

Vaccine-Induced Cellular Immunity against Bordetella pertussis: Harnessing Lessons from Animal and Human Studies to Improve Design and Testing of Novel Pertussis Vaccines

2021

View full text Add to dashboard Cite

show abstract

“…)/ml, and 10 g of polymyxin B (Sigma, St. Louis, Mo.)/ml. In order to neutralize the cytokineinducing activity of the endotoxin in the preparation of whole-cell antigens, the medium was supplemented with polymyxin B (3,6). The suspensions of spleen cells were supplemented with FHA (5 g/ml), PTd (5 g/ml), PRN (5 g/ml), and killed whole B. pertussis cells (10 6 cells/ml) or killed whole B. parapertussis cells (10 6 cells/ml).…”

Section: Cfumentioning

confidence: 99%

Reciprocal Protective Immunity againstBordetella pertussisandBordetella parapertussisin a Murine Model of Respiratory Infection

Watanabe

Nagai

2001

Infect Immun

View full text Add to dashboard Cite

The protective immunity induced by infection withWhooping cough caused by Bordetella pertussis is a serious disease in children. Commercial pertussis vaccines, which consist of killed B. pertussis cells or derived antigens, are very effective and have reduced the incidence of whooping cough very considerably. However, in addition to B. pertussis, Bordetella parapertussis also causes symptoms typical of whooping cough (22). The illness caused by B. parapertussis is sometimes as severe as that caused by B. pertussis (10). Outbreaks of infection by B. parapertussis have been reported in several countries (8,11,18). B. parapertussis is closely related to B. pertussis in terms of virulence and attachment factors, such as filamentous hemagglutinin (FHA), adenylate cyclase toxin, heat-labile toxin, and pertactin (PRN) (29). However, several reports suggest that pertussis vaccine has no or limited ability to protect against B. parapertussis (9, 13, 15, 27, 32). Stehr et al. reported that the efficacy of the acellular pertussis component diphtheria-tetanus-pertussis (DTP) vaccine and the whole-cell pertussis component DTP vaccine in children was 31% and Ϫ6%, respectively (27). Khelef et al. suggested that immunization with antigens derived from B. pertussis induce no protection against B. parapertussis in mice (13). These reports suggested that reciprocal protective immunity between the two species might not be induced. However, in these studies, subcutaneous or peritoneal injections were commonly used as methods of immunization. Mills et al. suggested that there might be a difference, in terms of the profiles of the protective immune response against B. pertussis, between the response after immunization by injection with vaccines and the response during convalescence after infection with B. pertussis (20). We postulated that immunization by natural infection of the two species might clarify the relationship between protection against B. pertussis and protection against B. parapertussis. To test our hypothesis, we infected mice by exposing them to an aerosol of B. pertussis or B. parapertussis. After mice had recovered, convalescent mice were investigated for protective responses against the two species of Bordetella, for levels of antigen-specific antibodies, and for splenocyte proliferation and cytokine secretion responses in vitro after stimulation by antigens. MATERIALS AND METHODSMice. Specific-pathogen-free female dd-Y mice were obtained from Japan SLC (Hamamatsu, Japan). All mice were 3.5 weeks old at the start of experiments.Bacterial strains and culture conditions. The phase I strain of B. pertussis strain 18-323 and B. parapertussis strain 23054 were used in this study. Cells were grown on Bordet-Gengou (BG) agar supplemented with 20% (vol/vol) defibrinated horse blood at 37°C.Bacterial antigens. Killed whole-cell B. pertussis or B. parapertussis antigens were prepared as described below. B. pertussis or B. parapertussis was cultured on BG plates for 30 h at 37°C. Cells were harvested in phosphate-buffered sali...

show abstract

“…Spleen cells from immunized mice were tested in vitro for secretion of cytokines in response to vaccine components as described previously [25]. Single‐cell suspensions of spleen cells (2.0×10 6 cells ml −1 in RPMI 1640 medium, from Life Technologies, Rockville, MD, USA, supplemented with 10% fetal calf serum and 10 μg ml −1 of polymyxin B) were incubated with FHA (5 μg ml −1 ), heat‐detoxified (80°C, 30 min) PT (5 μg ml −1 ), PRN (5 μg ml −1 ) and Fim (5 μg ml −1 ) separately at 37°C for 72 h in an atmosphere of 5% CO 2 in air [26,27]. Culture supernatants were obtained by centrifugation (450× g , 5 min, 4°C) and stored at −80°C prior to assays.…”

Section: Methodsmentioning

confidence: 99%

Evaluation of efficacy in terms of antibody levels and cell-mediated immunity of acellular pertussis vaccines in a murine model of respiratory infection

Watanabe

Komatsu²,

Sato³

et al. 2002

FEMS Immunology &Amp; Medical Microbiology

View full text Add to dashboard Cite

The efficacy of six acellular pertussis vaccines, prepared by various manufacturers in Japan, was investigated in a murine model of respiratory infection (aerosol challenge model) and a murine intracerebral (i.c.) challenge model. There was a good correlation between bacterial clearance from the lungs after aerosol challenge and the potency of vaccines as determined by i.c. challenge. The levels of antibodies against filamentous hemagglutinin were higher after immunizations with all tested vaccines than the levels of antibodies against pertussis toxin and pertactin. Spleen cells from mice immunized with each individual vaccine secreted interferon gamma (IFN-gamma) in response to stimulation by pertussis toxin, filamentous hemagglutinin and fimbriae. The production of interleukin-4 in response to each of the antigens tested was detected but was lower than that of IFN-gamma. However, antibody levels and cell-mediated immune responses were not correlated with the protective effects of the vaccines after aerosol challenge and after i.c. challenge.

show abstract

Induction of a specific antibody response to Bordetella pertussis antigens in cultures of human peripheral blood mononuclear cells

Cited by 6 publications

References 26 publications

Vaccine-Induced Cellular Immunity against Bordetella pertussis: Harnessing Lessons from Animal and Human Studies to Improve Design and Testing of Novel Pertussis Vaccines

Vaccine-Induced Cellular Immunity against Bordetella pertussis: Harnessing Lessons from Animal and Human Studies to Improve Design and Testing of Novel Pertussis Vaccines

Reciprocal Protective Immunity againstBordetella pertussisandBordetella parapertussisin a Murine Model of Respiratory Infection

Evaluation of efficacy in terms of antibody levels and cell-mediated immunity of acellular pertussis vaccines in a murine model of respiratory infection

Contact Info

Product

Resources

About